Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Deferoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 1/20 | 0.91 |
| ▸ | GAA | P10253 | 1/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | KDM4A | O75164 | 9/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.84 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.84 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.84 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deferoxamine SCHEMBL10579133 | 0.98 | KDM4E (0.91) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL18983317 | 0.98 | KDM4E (0.91) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1699778 | 0.95 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL119982 | 0.95 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| SCHEMBL30036991 | 0.95 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL7715593 | 0.95 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL3953046 | 0.94 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL9351925 | 0.94 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL2165915 | 0.93 | KDM4E (0.95) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1034134 | 0.93 | KDM4E (0.95) | KDM4ELMNAGAASMN1; SMN2KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3400 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | POLYAMYNA NANOTECH INC. (CA) | 2026-05-28 | — | — | US | claimed |
| WO-2025224448-A1 | STABLE BIORELEVANT COMPOSITIONS AND MEDIA FOR IN VITRO TESTING | BIORELEVANT.COM LIMITED (GB) | 2025-10-30 | — | — | WO | claimed |
| US-20250332118-A1 | NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA | LIVIONEX INC (US) | 2025-10-30 | — | — | US | claimed |
| US-20250319214-A1 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Ltd. (GB) | 2025-10-16 | — | — | US | claimed |
| CN-115443162-B | Drug injection device, system and method | 解决方案医疗公司 | 2025-05-06 | — | — | CN | claimed |
| US-20250064739-A1 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | AKAGERA MEDICINES, INC. (US) | 2025-02-27 | — | — | US | claimed |
| CN-119464378-A | Gene editing method of neutrophils | 电子科技大学 | 2025-02-18 | — | — | CN | claimed |
| EP-4504163-A1 | NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA | Livionex, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| EP-4452252-A2 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | Akagera Medicines, Inc. (US) | 2024-10-30 | — | — | EP | claimed |
| EP-4362989-A2 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Limited (GB) | 2024-05-08 | — | — | EP | claimed |
| WO-1999036055-A1 | AUTOCLAVABLE PHARMACEUTICAL COMPOSITIONS CONTAINING A CHELATING AGENT | NOVARTIS AG (CH) | 1999-07-22 | — | — | WO | claimed |
| US-5895786-A | Method for treating viral infections | NEW YORK BLOOD CENTER, INC. (US) | 1999-04-20 | — | — | US | claimed |
| EP-0904075-A1 | METHOD FOR TREATING VIRAL INFECTIONS | THE NEW YORK BLOOD CENTER, INC. (US) | 1999-03-31 | — | — | EP | claimed |
| WO-1997041855-A1 | METHOD FOR TREATING VIRAL INFECTIONS | NEW YORK BLOOD CENTER, INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0436005-B1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1995-03-29 | — | — | EP | claimed |
| EP-0313630-B1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME | DEUTSCHES AUSSÄTZIGEN HILFSWERK E.V. (DE) | 1992-09-16 | — | — | EP | claimed |
| EP-0436005-A1 | LABELED POLYPEPTIDE DERIVATIVES. | SANDOZ LTD (CH) | 1991-07-10 | — | — | EP | claimed |
| WO-1991001144-A1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1991-02-07 | — | — | WO | claimed |
| EP-0313630-A1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME. | DEUTSCHES AUSSATZIGEN HILFSWER (DE) | 1989-05-03 | — | — | EP | claimed |
| WO-1988008842-A2 | SUBSTITUTED 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME | DEUTSCHES AUSSÄTZIGEN HILFSWERK E.V. (DE) | 1988-11-17 | — | — | WO | claimed |